Further information

With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs - there is a pressing need for a forum which explores this increasingly normalized medical methodology.

Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, Bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.

The benefits of attending:
At this year’s conference there will once again be an array of networking opportunities:
• Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
• More than 4 hours of networking during the conference days
• Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year

Key reasons to attend:
• See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
• Explore the therapeutic potential of adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis
• Listen to how the latest platform trial case studies - such as that of the EPAD project and the MS Society initiative, are impacting pharmaceutical development
• Delve into the long-standing discussion of Bayesian vs. frequentist designs
• Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward

EARLY-BIRD RATES:
BOOK BY 14th DECEMBER AND SAVE £400
BOOK BY 31ST JANUARY AND SAVE £200
BOOK BY 14H FEBRUARY AND SAVE £100